PLXS — what changed in the latest 10-Q
A section-by-section comparison of PLXS's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-05-07 vs the prior 10-Q · 2026-02-05
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +40 | −24 | ~28 | 23 |
| Market risk (Item 3) | Text added/removed | 0 | −1 | ~3 | 3 |
| Controls & procedures | Text added/removed | 0 | 0 | ~2 | 0 |
| Risk factors | No material changes reported (points to the 10-K) | — | — | — | — |
| Other information | Text added/removed | +1 | −1 | 0 | 0 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Legal proceedings
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-05-07
Net sales. For the three months ended April 4, 2026, net sales increased $183.6 million, or 18.7%, as compared to the three months ended March 29, 2025. For the six months ended April 4, 2026, net sales increased $277.3 million, or 14.2%, as compared to the six months ended March 29, 2025.
During the six months ended April 4, 2026, net sales in the APAC segment increased $69.5 million, or 5.8%, as compared to the six months ended March 29, 2025. The increase in net sales was driven by overall net increased customer end-market demand and an increase of $27.7 million due to production r…
EMEA. Net sales for the three months ended April 4, 2026 in the EMEA segment increased $13.2 million, or 12.9%, as compared to the three months ended March 29, 2025. The increase in net sales was driven by overall net increased customer end-market demand.
During the six months ended April 4, 2026, net sales in the EMEA segment increased $30.2 million, or 14.8%, as compared to the six months ended March 29, 2025. The increase in net sales was driven by an increase of $17.3 million due to production ramps of new products for existing customers and over…
During the six months ended April 4, 2026, net sales in the Aerospace/Defense sector increased $57.9 million, or 17.4%, as compared to the six months ended March 29, 2025. The increase in net sales was driven by an increase of $62.8 million in production ramps of new products for existing customers …
Text removed vs the prior filing · source: 10-Q · 2026-02-05
Net sales. For the three months ended January 3, 2026, net sales increased $93.8 million, or 9.6%, as compared to the three months ended December 28, 2024.
Healthcare/Life Sciences. Net sales for the three months ended January 3, 2026 in the Healthcare/Life Sciences sector increased $91.9 million, or 24.6%, as compared to the three months ended December 28, 2024. The increase in net sales was driven by an increase of $53.9 million in production ramps o…
Industrial. Net sales for the three months ended January 3, 2026 in the Industrial sector decreased $16.4 million, or 3.7%, as compared to the three months ended December 28, 2024. The decrease in net sales was driven by a decrease of $10.3 million due to a disengagement with a customer and overall …
Cost of sales. Cost of sales for the three months ended January 3, 2026 increased $88.3 million, or 10.1%, as compared to the three months ended December 28, 2024. Cost of sales is comprised primarily of material and component costs, labor costs and overhead. For each of the three months ended Janua…
As compared to the three months ended December 28, 2024, the increase in cost of sales in the three months ended January 3, 2026 was primarily driven by an increase in net sales and an increase in fixed costs.
Market risk (Item 3)
Text removed vs the prior filing · source: 10-Q · 2026-02-05
million) to consolidated EBITDA. As of January 3, 2026, the borrowing rate under the Credit Facility was SOFR plus 1.00%. Borrowings under the 2018 NPA are based on a fixed interest rate, thus mitigating much of our interest rate risk. Based on our overall interest rate exposure, as of January 3, 20…
Other information
Text added vs the prior filing · source: 10-Q · 2026-05-07
(c) During the second quarter of fiscal 2026, Karen M. Rapp, a member of Plexus' board of directors, adopted a Rule 10b5-1 trading arrangement on February 2, 2026. This arrangement is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 4,000 shares of the Company's co…
Text removed vs the prior filing · source: 10-Q · 2026-02-05
(c) During the first quarter of fiscal 2026, none of our directors or Section 16 officers adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement" (as each term is defined in Item 408(a) of Regulation S-K), except that on November 20, 2025, Todd Kelsey, the …
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice